Ensaios Clínicos em Fase de Recrutamento

Atualmente, estão em fase de recrutamento para realização no Hospital da Luz os seguintes ensaios clinicos:

  • Ensaios clínicos na área da asma

    • Ensaio clínico TRIGGER

    “A 52 week, randomized, double blind, multinational, multicentre, active controlled, 3-arm parallel group trial comparing CHF 5993 200/6/12.5 µg pMDI (fixed combination of extrafine beclometasone dipropionate plus formoterol fumarate plus glycopyrronium bromide) to CHF 1535 200/6 µg pMDI (fixed combination of extrafine beclomethasone dipropionate plus formoterol fumarate) alone or on top of open-label tiotropium 2.5 µg Respimat® in patients with asthma uncontrolled on high doses of inhaled corticosteroids in combination with long-acting ß2-agonists.”

    Para mais informações:

  • Ensaios clínicos na área do carcinoma da mama

    • Ensaio clínico SANDPIPER 

    A phase III, double-blind, placebo-controlled, randomized study of taselisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with estrogen receptor-positive and HER2-negative locally advanced or metastatic breast cancer who have disease recurrence or progression during or after aromatase inhibitor therapy.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-003185-25/PT

    • Ensaio clinico NALA

    A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2-Directed Regimens in the Metastatic Setting.

    Mais informações em: https://clinicaltrials.gov/ct2/show/NCT01808573?term=PUMA-NER-1301&rank=1

    •  Ensaio clínico OLYMPIA

    A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003839-30/PT

    • Ensaio clínico PALLAS:

    A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005181-30/PT




  • Ensaios clínicos na área do carcinoma da próstata

    • Ensaio clínico VIABLE

    “A Randomized, Double Blind, Multicenter, Parallel-group, Phase III study to evaluate efficacy and safety of DCVAC/PCa versus Placebo in Men with metastatic Castration Resistant Prostate Cancer eligible for 1st line chemotherapy”

    Para mais informações:


    • Ensaio clínico ARAMIS

    A multinational, randomized, double-blind, placebo-controlled, phase III efficacy and safety study of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer

    Para mais informações:

  • Ensaios clínicos na área do carcinoma do esófago

    • Ensaio clínico MK3475-18A

    Phase III Randomized Open-label Study of Single Agent Pembrolizumab vs Physicians' Choice of Single Agent Docetaxel, Paclitaxel, or Irinotecan in Subjects with Advanced/Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Esophagus that have Progressed after First-Line Standard Therapy (KEYNOTE-181).

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002782-32/PT


  • Ensaios clínicos na área do carcinoma do estômago

    • Ensaio clinico TAS-102-302

    Randomized, Double-Blind, Phase 3 Study Evaluating TAS-102 plus Best Supportive Care (BSC) versus Placebo plus BSC in Patients with Metastatic Gastric Cancer Refractory to Standard Treatments.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-002683-16/PT


  • Ensaios clínicos na área da colite ulcerosa

    • Ensaio clínico GARDENIA

    “Phase III, randomized, multicenter double-blind, double-dummy study to evaluate the efficacy and safety of Etrolizumab compared with Infliximab in patients with moderate to severe active ulcerative colitis who are naive to TNF inhibitors.”

    Para mais informações:


  • Ensaios clínicos na área da diabetes

    • Ensaio clínico FIDELIO

    A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone, in addition to standard of care, on the progression of kidney disease in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000990-11/PT

    • Ensaio clínico FIGARO

    A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000950-39/PT

  • Ensaios clínicos na área da doença de Crohn

    • Ensaio clínico REVOLVE

    “A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of subjects with active Crohn’s disease.”

    Para mais informações:


  • Ensaios clínicos na área da esclerose múltipla

    • Ensaio Clínico COMB157G2302

    A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab versus teriflunomide in patients with relapsing multiple sclerosis.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-005419-33/PT

  • Ensaios clínicos na área da insuficiência cardíaca

    • Ensaio clínico RELAX AHF EU

    “A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients.”

    Para mais informações:


    • Ensaio clínico COMMANDER HF

    “A randomized, double-blind, event-driven, multicenter study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an episode of decompensated heart failure”.

    Para mais informações: 



    • Ensaio clínico TRANSITION

    “A multicenter, randomized, open label, parallel group study comparing pre-discharge and post-discharge treatment initiation with LCZ696 in heart failure patients with reduced ejectIon-fraction hospitalized for an acute decompensation event (ADHF)”

    Para mais informações:


  • Ensaios clínicos na área do tromboembolismo pulmonar

    • Ensaio clínico Hot PE

    “Home treatment of patients with low-risk pulmonary embolism with the oral factor xa inhibitor rivaroxaban: prospective management trial”

    Para mais informações:


Se estiver interessado em saber mais sobre algum dos ensaios clínicos referidos, poderá enviar um e-mail para ensaiosclinicos.lisboa@hospitaldaluz.pt e a equipa do Centro de Investigação Clínica do Hospital da Luz entrará em contacto consigo.

O envio deste e-mail não é garantia da participação num ensaio clínico.